91520-00-2

Usage

Uses

Used in Pharmaceutical Industry:
8-Methoxy-2H-chromen-3(4H)-one is used as a pharmaceutical agent for its anti-inflammatory properties, particularly in traditional Chinese medicine, where it is applied for its anti-itch and anti-inflammatory effects on the skin.
Used in Oncology:
In the field of oncology, 8-Methoxy-2H-chromen-3(4H)-one is used as a potential anti-cancer agent, with studies investigating its effects on various types of cancer. It is also utilized as a photosensitizer in photodynamic therapy, where it aids in the selective destruction of cancer cells upon exposure to light.
Used in Dermatology:
8-Methoxy-2H-chromen-3(4H)-one is used as a therapeutic agent in dermatology for treating skin disorders, capitalizing on its anti-inflammatory and anti-itch properties to alleviate symptoms and promote skin health.
Used in Virology Research:
In virology, 8-Methoxy-2H-chromen-3(4H)-one is used in research for its anti-viral activities, exploring its potential to inhibit viral replication and reduce the severity of viral infections.
Used in Cosmetics Industry:
8-Methoxy-2H-chromen-3(4H)-one may also be used in the cosmetics industry for its skin health benefits, particularly in formulations aimed at reducing inflammation and itching, thus improving the overall condition of the skin.

InChI:InChI=1/C10H10O3/c1-12-9-4-2-3-7-5-8(11)6-13-10(7)9/h2-4H,5-6H2,1H3

Upstream product

• 57543-59-6 8-methoxy-2H-chromene-3-carboxylic acid 
• 57543-69-8 8‐methoxy‐2H‐chromene‐3‐carbonitrile 
• 16336-25-7 8-methoxy-2H-1-benzopyran 
• 90-05-1 2-methoxy-phenol 
• 41580-71-6 1-methoxy-2-(prop-2-ynyloxy)benzene 
• 855933-36-7 (2-carboxymethoxy-3-methoxy-phenyl)-acetic acid 
• 108-24-7 acetic anhydride 
• 148-53-8 3-methoxy-2-hydroxybenzaldehyde 

Downstream Products

• 1026839-64-4 Dibenzyl-((R)-8-methoxy-chroman-3-yl)-amine 
• 81486-18-2 Carbonic acid ethyl ester (R)-3-hydroxy-chroman-8-yl ester 
• 104536-79-0 Carbonic acid ethyl ester (S)-3-nitrooxy-chroman-8-yl ester 
• 104536-66-5 Benzenesulfonic acid (R)-8-ethoxycarbonyloxy-chroman-3-yl ester 

Relevant academic research and scientific papers

Bifunctional Br?nsted Base Catalyst Enables Regio-, Diastereo-, and Enantioselective Cα-Alkylation of β-Tetralones and Related Aromatic-Ring-Fused Cycloalkanones

The catalytic asymmetric synthesis of both α-substituted and α,α-disubstituted (quaternary) β-tetralones through direct α-functionalization of the corresponding β-tetralone precursor remains elusive. A designed Br?nsted base-squaramide bifunctional catalyst promotes the conjugate addition of either unsubstituted or α-monosubstituted β-tetralones to nitroalkenes. Under these reaction conditions, not only enolization, and thus functionalization, occurs at the α-carbon atom of the β-tetralone exclusively, but adducts including all-carbon quaternary centers are also formed in highly diastereo- and enantioselective manner.

Rapid access to chroman-3-ones through gold-catalyzed oxidation of propargyl aryl ethers

The two-step: Chroman-3-ones are important intermediates for organic synthesis and medicinal chemistry. However, their syntheses require multiple steps and are not efficient. By using gold-catalyzed alkyne oxidation, this versatile heterocycle can be prepared in only two steps from readily available phenols and with mostly high efficiencies (see scheme).

Novel 2-aminotetralin and 3-aminochroman derivatives as selective serotonin 5-HT7 receptor agonists and antagonists

The understanding of the physiological role of the G-protein coupled serotonin 5-HT7 receptor is largely rudimentary. Therefore, selective and potent pharmacological tools will add to the understanding of serotonergic effects mediated through t

6- and 8-Hydroxy-3,4-dihydro-3-(dipropylamino)-2H-1-benzopyrans. Dopamine Agonists with Autoreceptor Selectivity

The dopamine agonist profiles of 3,4-duhydro-3-(3-dipropylamino)-2H-1-benzopyran-6- and 8-ol (4 and 5, respectively) were examined.Both 4 and 5 exhibited greater relative affinity for receptors labeled with the dopamine agonist ligand propylnorapomorphine than for those labeled with the dopamine antagonist ligand haloperidol.Both compounds attenuated the simulation of brain dopamine synthesis caused by γ-butyrolactone (GBL) and decreased the firing rate of substantia nigra dopamine neurons in rats.This profile of activity, together with the ability of the dopamine antagonist haloperidol to reverse the inhibition of dopamine neuronal firing, indicate that both compounds are brain dopamine agonists.

CERTAIN BENZO-(PYRANO AND THIOPYRANO)-PYRIDINES, USEFUL AS CNS AGENTS

Disclosed are the compounds of formula I STR1 wherein X represents oxygen or sulfur; ring A is unsubstituted or substituted by one to three identical or different substituents selected from hydroxy, hydroxy-lower alkyl, etherified hydroxy, etherified hydroxy-lower alkyl, acyloxy, acyloxy-lower alkyl, halogen, lower alkyl, trifluoromethyl, amino, mono-and di-lower alkylamino and acylamino; or ring A is substituted by one lower alkylenedioxy; R represents hydrogen, lower alkyl or aryl-lower alkyl; R 1 represents hydrogen, lower alkyl, lower alkylthio-lower alkyl, amino, acylamino, (amino, mono-or di-lower alkylamino)-lower alkyl, carboxy, lower alkoxycarbonyl, carbamoyl or mono-or di-lower alkylcarbamoyl; R 2 to R 5 represent hydrogen or lower alkyl; the dehydro derivatives thereof with a double bond at the 1, 2-position, or at the 1,10b-position in which case R 5 is absent; or a pharmaceutically acceptable salt thereof; methods for their synthesis; pharmaceutical compositions thereof; and use thereof as psychactive agents for the treatment of central nervous system disorders.